Canagliflozin review reports unclear changes in diabetes-related markers
In patients with diabetes and cardiovascular disease, canagliflozin did not clearly change the reported blood-sugar or body-size markers versus placebo. The abstract's favorable blood-pressure conclusion conflicts with its reported statistical test.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The reported comparisons did not establish differences from placebo in HbA1c, a blood-sugar marker, or body mass index, a body-size measure. The abstract also claims a significant blood-pressure reduction, although its reported test does not support that wording. These marker results do not establish fewer cardiovascular events, and no dose superiority can be inferred.
The blood-pressure conclusion conflicts with the reported statistical test. Effect-size units and follow-up lengths are unspecified, preventing a clear assessment of the magnitude, practical meaning or persistence of the reported changes.
What researchers found
Systolic blood pressure, the upper reading
Canagliflozin 100 mg versus placebo; P = 0.06. Follow-up length and effect-size units are unspecified.
Markers and clinical outcomes
The review examined HbA1c, body mass index and systolic blood pressure. These are measured markers, rather than cardiovascular events themselves. The abstract does not report whether treatment changed the occurrence of heart attacks or other clinical events.
Reading the conflicting conclusion
The blood-pressure test did not meet the usual threshold for statistical significance, despite the conclusion's wording. Likewise, nonsignificant blood-sugar and body-size results leave uncertainty; they do not prove that canagliflozin and placebo have identical effects.
The original publication
Effects of canagliflozin on cardiovascular disease risk factors in patients with type 2 diabetes: a systematic review and meta-analysis.
Aftabi H, Aftabi R
BMC Endocr Disord · 2025
- PubMed ID
- 40604628
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.